Navigation Links
Leaders from Pfizer, Novartis and J&J Challenge Industry to Disrupt R&D
Date:8/8/2012

NEW YORK, Aug. 8, 2012 /PRNewswire/ -- Pharmaceutical and biotech companies are preparing to hear more than 25 presentations, ranging from key behaviors that drive innovation to applying disruptive approaches to achieve pragmatic clinical trials, at the 2nd Annual Disruptive Innovations to Advance Clinical Trials (DPharm) conference. The event is scheduled for September 13-14, 2012 at the Fairmont Copley Plaza Hotel, Boston, MA. www.dpharmconference.com

Designed for innovative thinkers looking to take the high-level, systemic view needed to identify changes that can overcome inefficiencies in clinical trials, this TED-style event showcases innovations and leading practitioners in clinical research. Leading the event is:

  • Craig H. Lipset, Head of Clinical Innovation, Research & Development, Pfizer
  • John Orloff, MD, SVP, Global Development & Chief Medical Officer, Novartis Pharma AG
  • Andreas Koester, MD, PhD, VP, Clinical Trial Innovation & External Alliances, Janssen, Pharmaceutical Companies of Johnson & Johnson

"Featuring fresh ideas in a highly engaging format, DPharm has quickly emerged as THE event for creative leaders seeking to bring the changes in clinical research necessary to ensure the ongoing development of new medicines," comments Craig Lipset.

Co-Chair John Orloff adds, "The pharmaceutical industry is at a crossroads.  We can cling to the old business model and go the way of the dinosaurs. Or we can embrace disruptive technologies and innovations, already being piloted, to transform our industry and move us into a new era of productivity, for our patients. Do we have the will and the bold leadership to make it happen?  The 2nd Annual DPharm event discusses many of these opportunities as a catalyst towards a new paradigm."

As a Guest VIP Speaker, Karen Freidt, Lead, Navigation Center for Creativity, Collaboration & Innovation, NASA, talks about how NASA powers innovation in a heavily regulated high risk industry.

Over 250 attendees are anticipated. Companies participating in the event include Acorda Therapeutics, AG Mednet, Aptiv Solutions, Archimedes, AxxiTRIALS, Bill & Melinda Gates Foundation, Celtic Therapeutics, Clinical Ink, DrugDev.org, Eli Lilly, Endo Pharmaceuticals, Esperion Therapeutics, Geisinger Health System, GSK, Janssen, Merck Research Laboratories (MRL), Milestone Venture Partners, Novartis Pharma AG, Pfizer, J&J, NASA, RPS, Shire, Spaulding Clinical, Structural Genomics Consortium, Symphony Clinical Research, Target Health Inc., Transparency Life Sciences, ?WhatIf! Innovation and many more.

For more information, visit www.theconferenceforum.org, email Chealy@theconferenceforum.org or call 646 350 2580.

MEDIA CONTACT: Ciara Healy, PH: 646-350-2580 x310, Email: Chealy@theconferenceforum.org


'/>"/>
SOURCE The Conference Forum
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. PharmaVOICE Names Four inVentiv Health Associates Among "100 Most Inspiring" Leaders in Healthcare
2. Two Baltimore Business Leaders are BioHealth Innovation, Inc.s Newest Board Members
3. Advanced Animal Diagnostics Adds Sales & Marketing Leadership
4. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
5. GenScript Honored with the 2012 CRO Leadership Award
6. Innovation Leaders from Across Industries will Convene to Share Best Practices and Breakthrough Successes at Open Innovation Leadership Summit
7. BioMotiv Launches Novel Drug Development Operation, Names Leadership Team
8. CAS Names 2012 SciFinder® Future Leaders in Chemistry Program Participants
9. Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory Board
10. MD&M East 2012 to Feature FDA and Medical Technology Development Leaders
11. USC Marshall School of Business 6th Annual Leadership Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... Washington, USA (PRWEB) , ... December 02, 2016 ... ... role of innovative U.S.-owned and -operated small businesses in federally funded research and ... SPIE, the international society for optics and photonics . , As part of ...
(Date:12/4/2016)... , Dec. 3, 2016  In five studies ... Hematology (ASH) Annual Meeting and Exposition in ... engineering methods to improve the delivery of life-saving treatments ... new methods are designed to carry therapies directly to ... most, which could provide a substantial advantage over traditional, ...
(Date:12/2/2016)... ... 2016 , ... In anticipation of AxioMed’s exclusive cleanroom manufacturing ... President, Jake Lubinski will be traveling to Switzerland from December 5-10. Mr. Lubinski ... and Zurich to discuss the benefits of a viscoelastic disc. AxioMed received CE ...
(Date:12/2/2016)... , Dec. 2, 2016  The Multiple Myeloma Research ... the MMRF CoMMpass Study SM —the largest and most ... medicine in multiple myeloma—will be presented at the 58 ... & Exposition in San Diego ... optimize treatment strategies, as well as identify pathways and ...
Breaking Biology Technology:
(Date:11/21/2016)... 2016   Neurotechnology , a provider of ... announced that the MegaMatcher On Card fingerprint matching ... the NIST Minutiae Interoperability Exchange (MINEX) III ... steps of the evaluation protocol. ... of fingerprint templates used to establish compliance of ...
(Date:11/17/2016)... Nov. 17, 2016 Global Market Watch: ... (Disease-Based Banks, Population-Based Banks and Academics) market is to witness ... Private Biobanks shows the highest Compounded Annual Growth Rate (CAGR) ... region during the analysis period 2014-2020. North America ... 9.95% followed by Europe at 9.56% ...
(Date:11/16/2016)... , Nov. 16, 2016 Sensory Inc ... and security for consumer electronics, and VeriTran ... and retail industry, today announced a global partnership ... way to authenticate users of mobile banking and ... TrulySecure™ software which requires no specialized biometric ...
Breaking Biology News(10 mins):